|ASH 2019 Annual Meeting Highlights in Multiple Myeloma|
CME, CPE, CNE
Shaji K. Kumar, MD, FACP; Sagar Lonial, MD, FACP; Noopur Raje, MD; Saad Z. Usmani, MD, FACP
|Release Date: January 06, 2020|
Expiration Date: January 06, 2021
In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2019 American Society of Hematology (ASH) Annual Meeting. In this activity, you can view videos from the meeting and listen as they share their insights on a variety of abstracts covering topics including, but not limited to: key data from novel BCMA-directed therapy, predictive biomarkers of response to venetoclax-containing regimens, the evolving role of daratumumab in the treatment of myeloma, and novel quadruplet combination approaches.Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
|Begin, Earn CreditView Only, No Credit|